drugset / Trial / NCT05528653

Telehealth as a Modality to Increase the Uptake of PrEP Services in Black and Latino: "e-PrEP"

NCT05528653

Phase 4 Completed 75 enrolled Vivent Health Gilead Sciences · collab
NaSingle-groupOpen-labelPrevention

Summary

To evaluate if utilizing Telehealth medicine for access to HIV PrEP will engage more Black and Latino Men who have sex with Men (MSM)

Timeline

Start
2022-07-19
Primary completion
2024-07-31
Completion
2025-03-21

Drugs

EvaluationDrugModalityDoseRoute
Subject tenofovir alafenamide Small molecule

Indications

No indication recorded.